ReviewNutrition (Burbank, Los Angeles County, Calif.)2010
Update on melanocortin interventions for cachexia: progress toward clinical application.
Review in Nutrition (Burbank, Los Angeles County, Calif.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Combating chronic kidney disease-associated cachexia: A literature review of recent therapeutic approaches.BMC nephrology · 2025Review
- Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss in rats.The Journal of clinical investigation · 2024Article
- Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Altered glucose metabolism and insulin resistance in cancer-induced cachexia: a sweet poison.Pharmacological reports : PR · 2021Review
- Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease-associated cachexia.The Journal of clinical investigation · 2020Article
- Cachexia: Pathophysiology and Ghrelin Liposomes for Nose-to-Brain Delivery.International journal of molecular sciences · 2020Review
- JMV2894, a novel growth hormone secretagogue, accelerates body mass recovery in an experimental model of cachexia.Endocrine · 2017Article
- Article
- Hypothalamic activation is essential for endotoxemia-induced acute muscle wasting.Scientific reports · 2016Article
- Pathophysiology of anorexia in the cancer cachexia syndrome.Journal of cachexia, sarcopenia and muscle · 2015Review
- Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review.Gerontology · 2014Review
- Development of an UPLC mass spectrometry method for measurement of myofibrillar protein synthesis: application to analysis of murine muscles during cancer cachexia.Journal of applied physiology (Bethesda, Md. : 1985) · 2013Article
- Control of food intake by MC4-R signaling in the lateral hypothalamus, nucleus accumbens shell and ventral tegmental area: interactions with ethanol.Behavioural brain research · 2012Article
- The use of ghrelin and ghrelin receptor agonists as a treatment for animal models of disease: efficacy and mechanism.Current pharmaceutical design · 2012Review
- The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia.Journal of cachexia, sarcopenia and muscle · 2011Article
- Ghrelin and cachexia: will treatment with GHSR-1a agonists make a difference for patients suffering from chronic wasting syndromes?Molecular and cellular endocrinology · 2011Review
- Pathophysiology and treatment options for cardiac anorexia.Current heart failure reports · 2011Review
- Cancer cachexia: mechanisms and clinical implications.Gastroenterology research and practice · 2011Article
- Neuropeptides in the pathophysiology and treatment of cachexia.Current opinion in supportive and palliative care · 2010Review
- Animal models of anorexia and cachexia.Expert opinion on drug discovery · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Cachexia is a devastating syndrome of body wasting that is associated with multiple common chronic diseases including cancer, chronic kidney disease, and chronic heart failure. These underlying diseases are associated with increased levels of inflammatory cytokines and result in anorexia, increased resting energy expenditure, and loss of fat and lean body mass. Prior experiments have implicated the central melanocortin system in the hypothalamus with the propagation of these symptoms of cachexia. Pharmacologic blockade of this system using melanocortin antagonists causes attenuation of the signs of cachexia in laboratory models. Recent advances in our knowledge of this disease process have involved further elucidation of the pathophysiology of melanocortin activation and demonstration of the efficacy of melanocortin antagonists in new models of cachexia, including cardiac cachexia. In addition, small molecule antagonists of the melanocortin-4 receptor continue to be introduced, including ones with oral bioavailability. These developments generate optimism that melanocortin antagonism will be used to treat humans with disease-associated cachexia. However, to date, human application has remained elusive and it is unclear when we will know whether humans with cachexia would benefit from treatment with these compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.